(Adnkronos) - “Il nostro studio Amplify sulla leucemia linfatica cronica è stato individuato come uno dei migliori presentati quest'anno e questo ci dà davvero molta soddisfazione. Nello studio abbiamo portato una terapia fissa orale con due meccanismi d'azione che ha dato risultati importanti e anche una buona tollerabilità. L’intento è rendere possibile a tutti i pazienti di portare avanti questo trattamento e di avere questi successi terapeutici”. Così Paola Morosini, medical head oncology di Astrazeneca, in occasione del media tutorial promosso da Intermedia a Milano e dedicato al Congresso Ash, il 66esimo appuntamento annuale della Società Americana di Ematologia, svoltosi a San Diego dal 7 al 10 dicembre.
Category
🗞
NewsTranscript
00:00We are very excited and proud to be back at ASH, the American Society of Hematology.
00:12Our Amplify study in chronic lymphedema has been recognized as one of the best studies presented this year.
00:21It is a study in chronic lymphedema where we carried out an oral therapy with two mechanisms of action,
00:32which really gave important results and also good tolerability,
00:36thus making it possible for all patients to carry out this treatment and to have these therapeutic successes.
00:44However, we are not stopping here.
00:46We have also had data in chronic lymphedema, a rare and aggressive disease.
00:52For patients over 65 years of age and for this pathology, there have been no innovations in recent years.
01:00Instead, we arrive with the association with our molecule, with acalabrutinib, and therefore we are really happy.
01:07However, let's say that it is not enough.
01:09We have entered this area, which is super-specialistic, so really very complex.
01:14In this area, we want to continue to bring innovation and research, and we are doing this.
01:20With more than 100 studies in oncology in Italy, almost 10% are in hematology and, above all, they continue to grow over the years.
01:27So we are not stopping here.
01:29We have new molecules and, above all, we want to go to new pathologies,
01:33where we want to bring our contribution to take steps forward.
01:37And we hope to have other successes in this field.